Trial Profile
An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioavailability Study Among 3 New Formulations of Premarin 0.625 mg/Medroxyprogesterone Acetate (Mpa) 2.5 mg Compared With a Reference Formulation of Premarin/Mpa (Prempro) 0.625 mg/2.5 mg in Healthy Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2014
Price :
$35
*
At a glance
- Drugs Conjugated estrogens/medroxyprogesterone (Primary)
- Indications Menopausal syndrome; Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 19 Jun 2014 New trial record